Bayer Aktiengesellschaft engages in the development, production, and marketing of pharmaceuticals and health care products, agricultural products, and specialty materials. Segments As of December 31, 2008 the Bayer Group comprised three subgroups with operations subdivided into strategic business entities known as divisions (HealthCare) or business units (Crop- Science and MaterialScience). Their activities are aggregated into the six segments, including Pharmaceuticals, Consumer Health, Crop Protection, Environmental Science, BioScience, Materials, and Systems. HEALTHCARE SEGMENT Pharmaceuticals: This segment engages in the development, production and marketing of prescription pharmaceuticals, such as for the treatment of hypertension, cardiovascular diseases, infectious diseases, cancer and multiple sclerosis, and for contraception. Consumer Health: This segment engages in the development, production and marketing of over-the-counter medications, diagnostic products, nutritional supplements for humans and animals, veterinary medicines and animal grooming products. As of January 1, 2009, the company's pharmaceuticals comprised four business units: General Medicine, Specialty Medicine, Women’s Healthcare and Diagnostic Imaging. The company's General Medicine business unit focuses on products that are normally prescribed by general practitioners. In the United States, these products are marketed through the existing alliance with Schering-Plough. The Specialty Medicine unit possesses a portfolio in the areas of hematology, oncology and neurology, with products, including Kogenate, Nexavar, and Betaferon / Betaseron. The Women’s Healthcare and Diagnostic Imaging units offer products, such as yaz / Yasmin and Magnevist. The company’s Consumer Health segment comprises the Consumer Care, Medical Care and Animal Health divisions. On January 1, 2009, Bayer HealthCare’s Diabetes Care Division and its Medrad medical devices business were combined in the Medical Care Division. At Medrad, the company develops an injection platform for use in the diagnosis of cardiovascular diseases and in computed tomography and magnetic resonance imaging. The company invested in additional business areas, through the acquisition of iSense Corporation and Possis Medical, Inc. iSense is developing a minimally invasive continuous system for monitoring glucose in intercellular tissue. Possis Medical is a provider of mechanical thrombectomy devices used to treat narrowed or blocked arteries and veins. CROPSCIENCE SEGMENT Crop Protection: This segment engages in the development, production and marketing of a portfolio of fungicides, herbicides, insecticides and seed treatment products to meet a range of regional requirements. Environmental Science, BioScience: This segment engages in the development, production and marketing of a range of products for the green industry, garden care, non-agricultural pest and weed control, plant biotechnology and conventional seeds. Bayer CropScience comprises the Crop Protection, Environmental Science and BioScience business units. It provides products and integrated solutions that contribute to the production of agricultural raw materials. In Crop Protection, CropScience offers insecticides, fungicides, herbicides and seed treatments. The Environmental Science business unit makes use of the development and production capacities of Crop Protection and its active ingredients. The company’s BioScience business unit comprises the research, development and commercialization of seeds and solutions based on plant biotechnology and modern breeding methods. BioScience subsidiary Nunhems is a developer and supplier of vegetable seeds. The company’s activities for the agriculture market focus on three core crops – cotton, canola and rice. MATERIALSCIENCE SEGMENT Materials: This segment engages in the development, production and marketing of plastics granules, sheet and film. Systems: This segment engages in the development, production and marketing of polyurethanes for various applications and of coating and adhesive raw materials; production and marketing of inorganic basic chemicals.
bayer ag-sponsored adr (BAYA:XETRA)
Phone: 49 214 301
|Actavis plc||$295.41 USD||-2.95|
|Bristol-Myers Squibb Co||$65.80 USD||-0.20|
|GlaxoSmithKline PLC||1,535 GBp||+4.00|
|Novo Nordisk A/S||kr390.30 DKK||+5.10|
|View Industry Companies|
Sponsored Financial Commentaries
To contact BAYER AG-SPONSORED ADR, please visit www.bayer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.